Marie Thibault
Stock Analyst at BTIG
(3.91)
# 611
Out of 4,876 analysts
72
Total ratings
52.94%
Success rate
9.87%
Average return
Main Sectors:
Stocks Rated by Marie Thibault
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OBIO Orchestra BioMed Holdings | Initiates: Buy | $12 | $2.78 | +331.65% | 1 | Mar 20, 2025 | |
| EMBC Embecta | Upgrades: Buy | $26 | $9.64 | +169.71% | 2 | Nov 27, 2024 | |
| PODD Insulet | Maintains: Buy | $260 → $270 | $313.08 | -13.76% | 4 | Nov 8, 2024 | |
| MASI Masimo | Maintains: Buy | $166 → $170 | $168.21 | +1.06% | 3 | Oct 14, 2024 | |
| ESTA Establishment Labs Holdings | Maintains: Buy | $62 → $65 | $40.93 | +58.81% | 8 | Oct 14, 2024 | |
| BSX Boston Scientific | Maintains: Buy | $84 → $93 | $106.53 | -12.70% | 7 | Oct 14, 2024 | |
| HAE Haemonetics | Initiates: Buy | $112 | $73.80 | +51.76% | 1 | Sep 10, 2024 | |
| ATRC AtriCure | Maintains: Buy | $58 → $53 | $32.28 | +64.19% | 4 | Jul 31, 2024 | |
| DXCM DexCom | Maintains: Buy | $156 → $120 | $86.33 | +39.00% | 7 | Jul 26, 2024 | |
| XAIR Beyond Air | Downgrades: Neutral | n/a | $0.16 | - | 2 | Jun 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.18 | - | 3 | Oct 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 → $20 | $13.57 | +47.38% | 3 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $165 → $140 | $154.71 | -9.51% | 7 | Jun 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $4 → $3 | $3.80 | -21.05% | 3 | Mar 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $120 → $125 | $134.38 | -6.98% | 11 | Jan 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $7 | $1.38 | +407.25% | 1 | Jun 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $3.53 | - | 3 | Oct 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.49 | - | 1 | Jan 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $11 → $6 | $212.93 | -97.18% | 1 | Apr 9, 2020 |
Orchestra BioMed Holdings
Mar 20, 2025
Initiates: Buy
Price Target: $12
Current: $2.78
Upside: +331.65%
Embecta
Nov 27, 2024
Upgrades: Buy
Price Target: $26
Current: $9.64
Upside: +169.71%
Insulet
Nov 8, 2024
Maintains: Buy
Price Target: $260 → $270
Current: $313.08
Upside: -13.76%
Masimo
Oct 14, 2024
Maintains: Buy
Price Target: $166 → $170
Current: $168.21
Upside: +1.06%
Establishment Labs Holdings
Oct 14, 2024
Maintains: Buy
Price Target: $62 → $65
Current: $40.93
Upside: +58.81%
Boston Scientific
Oct 14, 2024
Maintains: Buy
Price Target: $84 → $93
Current: $106.53
Upside: -12.70%
Haemonetics
Sep 10, 2024
Initiates: Buy
Price Target: $112
Current: $73.80
Upside: +51.76%
AtriCure
Jul 31, 2024
Maintains: Buy
Price Target: $58 → $53
Current: $32.28
Upside: +64.19%
DexCom
Jul 26, 2024
Maintains: Buy
Price Target: $156 → $120
Current: $86.33
Upside: +39.00%
Beyond Air
Jun 25, 2024
Downgrades: Neutral
Price Target: n/a
Current: $0.16
Upside: -
Oct 6, 2023
Downgrades: Neutral
Price Target: n/a
Current: $2.18
Upside: -
Aug 16, 2023
Maintains: Buy
Price Target: $19 → $20
Current: $13.57
Upside: +47.38%
Jun 8, 2023
Maintains: Buy
Price Target: $165 → $140
Current: $154.71
Upside: -9.51%
Mar 29, 2023
Maintains: Buy
Price Target: $4 → $3
Current: $3.80
Upside: -21.05%
Jan 26, 2023
Maintains: Buy
Price Target: $120 → $125
Current: $134.38
Upside: -6.98%
Jun 24, 2022
Maintains: Buy
Price Target: $9 → $7
Current: $1.38
Upside: +407.25%
Oct 13, 2021
Downgrades: Neutral
Price Target: n/a
Current: $3.53
Upside: -
Jan 21, 2021
Downgrades: Neutral
Price Target: n/a
Current: $0.49
Upside: -
Apr 9, 2020
Maintains: Buy
Price Target: $11 → $6
Current: $212.93
Upside: -97.18%